STAT+: Pharmalittle: Private equity moving to buy clinical trials firms; data provider limits media access to drug prices
STAT News
DECEMBER 2, 2022
And a fragmented clinical trials industry has made it a prime target for private equity, which often consolidates markets by merging companies. And a fragmented clinical trials industry has made it a prime target for private equity, which often consolidates markets by merging companies.
Let's personalize your content